Avience Biomedicals IPO Subscription Status
The Avience Biomedicals IPO has been subscribed 385.4x times overall. Retail investors have shown interest with bids for 401.36x the shares available. The Non-Institutional Investor (NII) category has been subscribed 597.63x. Qualified Institutional Buyers (QIBs) have subscribed 196.77x. Data last updated on 11 Jul, 05:43 PM.
The IPO subscription period has ended. Given the strong demand, the allotment process is expected to be highly competitive. The issue opened on 18 Jun, 2026 and closes on 22 Jun, 2026. The shares are expected to list on stock exchanges on 25 Jun, 2026.
Table of Contents
Live Bidding
| Category | Offered | Applied | Bid Details | TIMES |
|---|---|---|---|---|
|
Anchor Investors
|
4,09,800 | - |
-
of 4,09,800
|
1.00x |
|
QIB
|
2,73,600 | 5,38,37,400 |
5,38,37,400
of 2,73,600
|
196.77x |
|
NII
|
2,07,000 | 12,37,09,800 |
12,37,09,800
of 2,07,000
|
597.63x |
|
Retail
|
4,81,200 | 19,31,32,800 |
19,31,32,800
of 4,81,200
|
401.36x |
| TOTAL | 9,61,800 | 37,06,80,000 |
37,06,80,000
-
|
385.40x |
Last Updated: 11 Jul 2026, 05:43 PM
Retail Allotment
High demand detected. The retail category is heavily oversubscribed, making the allotment a lottery where only 1 out of every 402 applicants will be successful.
Market Sentiment
Strong grey market premium of 69.7% suggests exceptional listing gains and high bullish sentiment among traders.
Institutional Backing
Massive institutional interest with QIBs subscribing 196.77x. This often signals long-term confidence from professional funds.
Day-wise Subscription History
Subscription trends over the last 3 days
| Date | Total | ||
|---|---|---|---|
|
22 Jun 2026
DAY 3
|
385.32x
|
||
|
QIB
196.77x
NII
597.23x
Retail
401.36x
|
|||
|
19 Jun 2026
DAY 2
|
43.79x
|
||
|
QIB
-x
NII
66.36x
Retail
58.97x
|
|||
|
18 Jun 2026
DAY 1
|
10.75x
|
||
|
QIB
-x
NII
13.49x
Retail
15.69x
|
|||
IPO Guru on Android
Get live GMP alerts, subscription updates, and allotment status directly on your phone. Fast, Free, and Secure.
Avience Biomedicals IPO Allotment Probability
Odds marked with applicant counts are computed from the exchange's actual application data (applicants ÷ allotment slots); others assume minimum-size bids at the current subscription multiple. Retail and HNI allotment is by SEBI-mandated lottery of the minimum application when oversubscribed; QIB allotment is proportionate. Numbers move until subscription closes. This is not investment advice.
What Does This Subscription Data Mean?
IPO subscription data tells you how much demand exists for the shares being offered, broken down by investor category. Understanding each category helps you gauge the real sentiment behind the numbers:
- QIB (Qualified Institutional Buyers) — includes mutual funds, FIIs, insurance companies, and banks. QIBs do deep due diligence before bidding. A QIB subscription above 10x is a strong institutional endorsement. Watch QIB numbers closely on the final day — they often hold back and flood in after 3 PM.
- NII / HNI (Non-Institutional Investors) — high-net-worth individuals bidding above ₹2 lakh. NII allotment is proportionate (not lottery), so higher NII subscription means smaller per-lot allotment. Big HNI (B-HNI) bids above ₹10 lakh; Small HNI (S-HNI) bids ₹2–10 lakh.
- Retail — individual investors bidding up to ₹2 lakh. When retail is below 1x, everyone who applied gets full allotment. When oversubscribed, SEBI mandates a computerised lottery — only 1 lot per successful applicant regardless of how many lots you apply for.
- Overall Subscription — a blended multiple across all categories. A total subscription above 10x is considered strong; above 50x is exceptional and usually predicts strong listing gains.
Data sourced from BSE/NSE. Subscription numbers are updated during market hours (10 AM – 5 PM IST) on active subscription days.
Frequently Asked Questions
What is the current subscription status of Avience Biomedicals IPO?
As of IPO close date (22 Jun, 2026), the Avience Biomedicals IPO is subscribed 385.40x times. Retail category is 401.36x, and NII is 597.63x subscribed.
When is the allotment date for Avience Biomedicals IPO?
The allotment for Avience Biomedicals IPO is expected to be finalized on 23 June, 2026.
What is the GMP of Avience Biomedicals?
The Grey Market Premium (GMP) for Avience Biomedicals is currently ₹145, indicating a potential listing gain of 69.7%.
When will Avience Biomedicals IPO list on the stock market?
Avience Biomedicals is scheduled to list on BSE and NSE on 25 June, 2026.
What are the chances of getting allotment in Avience Biomedicals IPO?
The retail category is oversubscribed at 401.36x, meaning allotment is by lottery. Statistically, approximately 1 in 402 applicants will receive allotment. Applying with multiple family member accounts (each at minimum lot size) improves your cumulative odds.
What does QIB subscription of 196.77x mean for Avience Biomedicals IPO?
Strong — QIBs (mutual funds, FIIs, insurance companies) have subscribed 196.77x, indicating high institutional conviction. Heavy QIB demand is historically one of the strongest predictors of a positive listing.
How to check Avience Biomedicals IPO allotment status?
After the allotment date (23 Jun, 2026), you can check your Avience Biomedicals IPO allotment status on IPO Guru's allotment checker, on the BSE/NSE website using your PAN or application number, or through your broker's app.
Explore Avience Biomedicals IPO Further
Track every stage of this IPO from subscription to listing:
Discussion 0
No comments yet
Be the first to share your thoughts!